Prevalence and prognostic value of sarcopenic obesity in patients with cancer: A systematic review and meta-analysis
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The aim of this study was to conduct a systematic review and meta-analysis of observational studies to estimate the overall prevalence and prognostic value of sarcopenic obesity (SO) in patients with cancer. We searched PubMed, Embase, Web of Science and the Cochrane Library for observational studies reporting the prevalence of SO and its prognosis in patients with cancer from inception to December 2020. The pooled prevalence, hazard ratios (HRs), odds ratios (ORs) and their 95% confidence intervals (CIs) of data extracted from the studies were calculated. We included 10 004 patients with cancer from 38 studies. The pooled prevalence of SO in this group of patients was 20% (95% CI, 17%-24%). Meta-analysis showed SO was significantly associated with poor overall survival (HR, 1.83; 95% CI, 1.41-2.38), recurrence-free survival (HR, 2.10; 95% CI, 1.57-2.80), disease-free survival (HR, 1.94; 95% CI, 1.01-3.74), postoperative complications (OR, 3.01; 95% CI, 2.08-4.33), and prolonged hospital length of stay (OR, 5.69; 95% CI, 2.76-11.74). The results for the relationship between SO and chemotherapy toxicity were inconsistent and controversial. Current limited evidence suggested that SO may be associated with poor cancer-specific survival (HR, 5.00; 95% CI, 1.40-16.70), but not progression-free survival (HR, 0.61; 95% CI, 0.32-1.16). The present review indicated SO is common in patients with cancer and is significantly associated with several poor outcomes. Therefore, it is necessary to diagnose and screen for SO in patients with cancer in the future, and appropriate interventions should be further explored to improve the prognosis of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At present, the exact mechanism of SO in patients with cancer is unclear, but it is probably due to the higher levels of systemic inflammatory markers and insulin resistance, which affects fat metabolism and increases the loss of muscle mass resulting in SO [39], [40].”
From Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis (2024) · cites this paper as [39]
In the citing paper
“A recent paper by Gaoand and colleagues pooled 38 studies including more than 10,000 patients, identified a prevalence of sarcopenic obesity in 20 % of oncological patients, associated with worse OS (HR 1.82), recurrence-free survival (HR 2.10), DFS (HR 1.94), and postoperative complications (OR 3.01) [39].”
From Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis (2024) · cites this paper as [39]
In the citing paper
“A recent paper by Gaoand and colleagues pooled 38 studies including more than 10,000 patients, identified a prevalence of sarcopenic obesity in 20 % of oncological patients, associated with worse OS (HR 1.82), recurrence-free survival (HR 2.10), DFS (HR 1.94), and postoperative complications (OR 3.01) [39].”
From Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis (2024) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Kalinkovich, A., & Livshits, G. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.008 · Cited by 882
Srikanthan, P., Hevener, A. L., & Karlamangla, A. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010805 · Cited by 600
Sarcopenic obesity and inflammation in the InCHIANTI study
Schrager, M. A., Metter, E. J., Simonsick, E., Ble, A., Bandinelli, S., Lauretani, F., & Ferrucci, L. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00627.2006 · Cited by 594
Baracos, V. E., & Arribas, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx810 · Cited by 362
Clinical implications of sarcopenic obesity in cancer
Carneiro, I. P., Mazurak, V. C., & Prado, C. M. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0546-5 · Cited by 162
Rier, H. N., Jager, A., Sleijfer, S., van Rosmalen, J., Kock, M. C. J. M., & Levin, M.-D. (2017) · The Breast · doi:10.1016/j.breast.2016.10.014 · Cited by 149
Martin, L., Hopkins, J., Malietzis, G., Jenkins, J. T., Sawyer, M. B., Brisebois, R., MacLean, A., Nelson, G., Gramlich, L., & Baracos, V. E. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6652-x · Cited by 139
Sarcopenic obesity: research advances in pathogenesis and diagnostic criteria
Xie, W.-Q., Xiao, G.-L., Fan, Y.-B., He, M., Lv, S., & Li, Y.-S. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01435-9 · Cited by 86
Cited by
Sarcopenic obesity in older adults: a clinical overview
Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00943-z · Cited by 355
“…effects on cancer outcomes and treatment (decreased overall 26,32,36 , recurrence-free 26,32 and disease-free survival 26 , surgical complications 26,27,30,38 , prolonged hospital length of stay (LOS) 26 , decreased tolerance to therapy (dose-limiting toxicity risk) 27 ), increased risk of…”
InfluentialSarcopenic obesity and health outcomes: An umbrella review of systematic reviews with meta‐analysis
Veronese, N., Ragusa, F. S., Pegreffi, F., Dominguez, L. J., Barbagallo, M., Zanetti, M., & Cereda, E. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13502 · Cited by 56
Chiloiro, G., Cintoni, M., Palombaro, M., Romano, A., Reina, S., Pulcini, G., Corvari, B., Di Franco, S., Meldolesi, E., Egidi, G., et al. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100789 · Cited by 21
Zhang, Y., Bellafronte, N. T., Najafitirehshabankareh, G., Jimenez, M. H., Jaeger-McEnroe, E., Plourde, H., Hendrickson, M., & Gillis, C. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108743 · Cited by 4
Metadata
- Authors
- Gao, Q., Hu, K., Gao, J., Shang, Y., Mei, F., Zhao, L., Chen, F., & Ma, B.
- Venue
- Nutrition
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 101
- Pages
- 111704
- ISSN
- 0899-9007 (ISSN-L)
- OpenAlex
- W4224250922
- Cited by
- 56
- References
- 13
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.